HÁJEK, Roman, Jana ČUMOVÁ, Anna POTÁČOVÁ, Irena KASALOVÁ, Ondrej ŠEDO and Zbyněk ZDRÁHAL. Proteomic Analysis of Multiple Myeloma Cells Targeted with Bortezomib. In ESH Conference. Mechanisms of cell death and disease: advances in therapeutic intervention and drug development. 2008.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Proteomic Analysis of Multiple Myeloma Cells Targeted with Bortezomib
Name in Czech Proteomická analýza lidských myelomových buněk ovlivněných přídavkem bortezomibu
Authors HÁJEK, Roman, Jana ČUMOVÁ, Anna POTÁČOVÁ, Irena KASALOVÁ, Ondrej ŠEDO and Zbyněk ZDRÁHAL.
Edition ESH Conference. Mechanisms of cell death and disease: advances in therapeutic intervention and drug development. 2008.
Other information
Original language English
Type of outcome Presentations at conferences
Field of Study 30200 3.2 Clinical medicine
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
Organization unit Faculty of Science
Keywords in English Multiple Myeloma; Bortezomib; proteomics
Tags bortezomib, multiple myeloma, proteomics
Tags International impact
Changed by Changed by: Mgr. Anna Potáčová, Ph.D., učo 44190. Changed: 11/4/2010 12:05.
Abstract
Introduction: Multiple myeloma (MM) is still an incurable disease characterized by the clonal expansion of malignant plasma cells. New anticancer drugs further improve prognosis of myeloma patients. Despite promising clinical activity, some patients with MM failed to respond to bortezomib therapy. The aim of this study was to evaluate changes in protein expression of myeloma cell line ARH-77 after bortezomib treatment. Materials and methods: Myeloma cell line ARH-77 was treated with bortezomib (5 – 20nM) for various periods of time. The proteins contained in total myeloma cell lysate were separated by 2-dimensional polyacrylamide gel electrophoresis (2-DE) and the differentially expressed proteins between the untreated (control) and treated cell lines were excised and identified by mass spectrometry. Results: There were analyzed 94 proteins differentially expressed between treated and control cells; total of 34 protein spots were upregulated: proteins involved in regulation of apoptosis, chaperons/stress related proteins, proteolysis of ubiquitin/protein degradation and cytoskeleton proteins. Sixty protein spots were downregulated: proteins involved in synthesis, regulation of apoptosis, chaperons/stress related proteins, regulation of cell cycle proteins, proteins connected to glycolysis and proteolysis of ubiquitin/protein degradation and antioxidant/redox proteins. Conclusion: Employing optimized proteomic approach we identified 94 proteins with altered expression after bortezomib treatment.
Links
LC06027, research and development projectName: Univerzitní výzkumné centrum - Česká myelomová skupina (Acronym: LC MGUS)
Investor: Ministry of Education, Youth and Sports of the CR, University Research Centre - Czech Myeloma Group
MSM0021622415, plan (intention)Name: Molekulární podstata buněčných a tkáňových regulací
Investor: Ministry of Education, Youth and Sports of the CR, Molecular basis of cell and tissue regulations
MSM0021622434, plan (intention)Name: Od klasických prognostických markerů ke klinicky aplikovatelným farmakogenomickým a farmakoproteomickým projektům u mnohočetného myelomu a monoklonálních gamapatií
Investor: Ministry of Education, Youth and Sports of the CR, From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies
NR9317, research and development projectName: Prognostický význam klonálních chromosomových aberací při použití nových léčebných metod u mnohočetného myelomu
PrintDisplayed: 2/5/2024 17:11